XB
Xenetic Biosciences, Inc.
XBIO · NASDAQ
$2.99 +6.41% (+$0.18)
1M -21.52%
Market Cap $6.85M
P/E Ratio -
Div. Yield -
ROE 40.62%
Bulios Fair Price
$3.79
26.8% upside
Current Price
$2.99
Undervalued Fair Value Overvalued
According to Bulios Fair Price, XBIO is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
87 /100
Cheap P/B 1.13x
P/S 2.10x
EV/FFO N/A
Growth
78 /100
Growing Book val. growth 18.47%
Rev. growth 20.36%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 81.01%
Gross margin 100.00%
FCF margin 70.93%
Quality
6 /100
Poor ROA 35.52%
ROIC 43.50%
Asset turnover 0.47x
Debt
100 /100
Low Current ratio 7.43x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
40 /100
Moderate EPS volatility 19.59%
Beta 2.24x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about XBIO
Online
Sector
Healthcare
Industry
Biotechnology
CEO
James F. Parslow
Employees
2
Headquarters
Framingham
Upcoming events
06 NOV
Earnings
Upcoming earnings report